Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00018902 · ClinicalTrials.gov registry record · Phase 2
Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)
A Phase 2 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 2
- Development phase
- 334
- Enrollment target
NCT00018902 is a Phase 2 study that has completed, run by University of Pittsburgh. The registered enrollment target is 334 participants.
The verdict
NCT00018902, a Phase 2 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 334 participants
- Enrollment target
Study Summary
The purpose of the study is to determine how best to treat adolescents with depression that is "resistant" to the first SSRI antidepressant they have tried. Participants receive one of three other antidepressant medications, either alone or in combination with cognitive behavioral therapy.
Interventions
- BEHAVIORAL Cognitive Behavioral Therapy (CBT)
- DRUG Fluoxetine
- DRUG Citalopram
- DRUG Venlafaxine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 334 participants |
| Start Date | 2001-01 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00018902
The ClinicalTrials.gov registry entry for NCT00018902 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 334 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cognitive Behavioral Therapy (CBT) is the first listed.
NCT00018902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00018902 about?
NCT00018902 is a clinical study titled "Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)". The purpose of the study is to determine how best to treat adolescents with depression that is "resistant" to the first SSRI antidepressant they have tried. Participants receive one of three other antidepressant medications, either alone or in combination with cognitive behavioral therapy.
What is the current status of trial NCT00018902?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 334 participants. The study started on 2001-01. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00018902?
The interventions under investigation include: Cognitive Behavioral Therapy (CBT) (BEHAVIORAL), Fluoxetine (DRUG), Citalopram (DRUG), Venlafaxine (DRUG).
Who is sponsoring clinical trial NCT00018902?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.